List of Exparel drug patents
Exparel is owned by Pacira Pharms Inc.
Exparel contains Bupivacaine.
Exparel has a total of 8 drug patents out of which 0 drug patents have expired.
Exparel was authorised for market use on 28 October, 2011.
Exparel is available in injectable, liposomal;injection dosage forms.
Exparel can be used as method of treating pain, for example, via infiltration for local analgesia or via nerve block, for example, nterscalene brachial plexus for regional analgesia, method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia, method of treating pain, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia, method of providing local or regional analgesia via infiltration for local analgesia or via interscalene brachial plexus nerve block or femoral nerve block for regional analgesia, method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia.
The generics of Exparel are possible to be released after 22 January, 2041.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033495 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11179336 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11278494 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11426348 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11452691 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11357727 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11311486 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| US11304904 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Mar 22, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: Method of providing postsurgical pain management, for example, via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of treating pain, for...
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
EXPAREL family patents
12
United States
1
China
1
United Kingdom
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic